CD8A and neoplasm: Our results shed light on the clonal T cell response to immune checkpoint blockade in ESCC, which has important implications for the design of immunotherapy to increase the clone size of existing tumor-reactive T cell clonotypes and/or recruitment of additional tumor-specific CD8+ T cells with replicative compacity27.